Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Secreted tumor antigens - immune biomarkers for diagnosis and therapy


With the advent of immunotherapies for cancer, there is growing interest in the identification of tumor antigens. Tumor antigens are self-molecules altered through genetic mutations (neoantigens), protein truncation, protein misfolding or abnormal post translational modifications. To induce an immune response, tumor antigens need to be secreted into the tumor environment and presented to the immune system in the draining lymph nodes, resulting in the generation of tumor-specific effector cells and antibodies. Cytotoxic T cells (CTL) are thought to be responsible for killing of tumor cells, and several recent studies have used MS, combined with exome/transcriptome sequencing and bioinformatics, to identify their cognate peptide ligands on tumor MHC class I molecules. Circulating (serum) antibodies have been more widely used to identify tumor antigens in a range of human cancers, using 2-D western blots, immunoaffinity and microarray technologies. More specific antibody probes have been generated by harvesting antibodies directly from antibody secreting cells (ASC) through in vitro cultures of lymph node cells (ASC-probes) or B cell immortalization. Further identification and characterization of tumor antigens is likely to have important implications for cancer diagnostic and biomarker discovery, immune profiling, and the development of cancer vaccines and targeted immunotherapies. This article is protected by copyright. All rights reserved.

Type Journal
ISBN 1615-9861 (Electronic) 1615-9853 (Linking)
Authors Meeusen, E. N.; Lim, E.; Mathivanan, S.
Responsible Garvan Author Prof Elgene Lim
Publisher Name PROTEOMICS
Published Date 2017-12-20
Published Volume 17
Published Issue 23-24
Published Pages 1600442
Status Always Electronic
DOI 10.1002/pmic.201600442
URL link to publisher's version